Cesnicabtagene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of adult human differentiated autologous T-lymphocytes that have been ex vivo expanded and transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, cesnicabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.

**Synonyms:** - ARI 0002h - ARI-0002h - ARI0002h - Autologous Differentiated Anti-BCMA CAR T-cells ARI0002h - CARTBCMA ARI0002h - CESNICABTAGENE AUTOLEUCEL - Differentiated Anti-BCMA Autologous CAR T Cells ARI0002h